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Abstract
Background: Autoimmune thyroid diseases including Graves’ disease and Hashimoto’s thyroiditis are caused by
immune response to self-thyroid antigens. The rare situation of hyperthyroidism with Graves’ disease in twins has
been reported in a very few case reports in literature.
Case presentation: We present monozygotic female twins developing consecutively Graves’ disease within five
years. One year before the diagnosis of Graves’ disease was established in the first twin, the mother developed a
toxic thyroid nodule with hyperthyroidism leading to hemi thyroidectomy. Both the mother and the twins were
cigarette smokers. The twins were treated with carbamizole and this therapy led to normalization of thyroid
stimulating hormone and thyroxine.
Conclusion: This case report supports the hypothesis that a genetic factor as well as an environmental factor
(cigarette smoking) might be of great importance in the aetiology of Graves’ disease.
Background
The prevalence of thyroid disorders in the general popula-
tion is small where hyperthyroidism seems to be less fre-
quent than hypothyroidism. Kasagi et al. assessed thyroid
function in the Japanese population [1]. Of the 1,818 ex-
aminees, 12 persons (0.7%) had manifest hypothyroidism,
105 persons (5.8%) showed subclinical hypothyroidism, 13
persons (0.7%) presented manifest thyrotoxicosis, and 39
persons (2.1%) suffered from subclinical thyrotoxicosis.
Hollowell et al. investigated 16,533 people in the USA [2].
Hypothyroidism was found in 4.6% of the U.S. population
(0.3% clinical and 4.3% subclinical) and hyperthyroidism
in 1.3% (0.5% clinical and 0.7% subclinical).
Graves’ disease is a specific form of hyperthyroidism.
Autoimmune thyroid diseases, including Graves’ disease
and Hashimoto’s thyroiditis, are due to complex interac-
tions between environmental and genetic factors. There
are data from epidemiological, family, and twin studies
demonstrating a strong genetic influence on the develop-
ment of autoimmune thyroid diseases [3,4]. The rare situ-
ation of hyperthyroidism with Graves’ disease in twins has
been reported in a very few case reports in literature [5-7].
Goldyn et al. described the serendipitous and simultan-
eous case of Graves’ disease in 6-year old female twins [5].
Mizukami et al. reported the case of Graves’ disease in
identical twins with mental disorder [6]. Mimaru et al. de-
scribed Graves’ disease in two pairs of female monozygotic
twins [7]. They assumed that a genetic factor may be of
great importance in the aetiology of Graves’ disease.
We present the case of monozygotic female twins de-
veloping consecutively Graves’ disease within five years.
The mother of the twins was diagnosed one year before
the diagnoses of Graves’ disease in the first twin with a
toxic thyroid nodule with hyperthyroidism leading to
hemi thyroidectomy.
Case presentation
The description of this case report is in compliance with
the Helsinki Declaration. In 2007, the mother of the un-
married twin A, who was born in 1980 and aged 26 at that
time, noticed a swelling of her daughters’ neck. Later, she
observed a set look. Due to these findings, she sent her
daughter in April 2008 to a medical doctor who made the
diagnoses of Graves’ disease based on the laboratory re-
sults (Table 1). A therapy with carbamizole was started
with 30 mg per day and was then reduced to 10 mg per
day. This therapy led to a normalization of the reduced
TSH (thyroid stimulating hormone) and the increased
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fT4 (thyroxine) (Figure 1). However, the compliance of
carbamizole intake was weak and the dosage of car-
bamizole had to be changed several times. During drug
therapy, the swelling of the neck became reduced. Due to
further normalization of the laboratory results, the medi-
cation with carbamizole was stopped in autumn 2008.
TSH and fT4 were measured later in irregular intervals
due to mal-compliance of the patient. In the case history
of twin A, tonsillectomy was performed in 1987, a pneu-
mothorax in 2006 was treated conservatively, in 2007 she
underwent hallux valgus correction and in 2008 varicose
vein stripping. She started smoking cigarettes as a teenager
and smokes 5–6 cigarettes a day.
In January 2012, the unmarried twin B aged 32 years
went to the family doctor of twin A due to symptoms
such as tiredness, dizziness, heart palpitations and sweat-
ing. The mother noticed a gaze. The patient herself
remarked an increase in the collar size. Laboratory
analyses revealed Graves’ disease (Table 1), and a treat-
ment with carbamizole 20 mg per day was started. Due
to normalization of fT4 (Figure 2) the dosage of
carbamizole was reduced to 15 mg per day. The therapy
was continued for one year. In the case history of twin B,
varicose vein stripping was done in 2006. She also started
smoking cigarettes as a teenager and smokes 5–10 ciga-
rettes per day.
In the family history, the twin’s mother born in 1947
developed in 2006 at the age of 59 years a toxic thyroid
nodule with hyperthyroidism leading to surgical therapy
with hemi thyroidectomy. The resulting hypothyroidism
was treated initially with 0.1 mg L-thyroxine and later
with 0.05 mg L-thyroxine. In January 2012, she devel-
oped rheumatoid arthritis which was treated initially
with prednisone and later with 20 mg leflunomide. Vita-
min D deficiency was treated with 800 mg vitamin D
daily. In the medical history of the mother, coronary
Table 1 Laboratory results upon diagnosis
Twin A Twin B
April 2008 January 2012
TSH [0.25-4.0 mU/l] < 0.003 * < 0.004 *
fT4 [6.8-18 pmol/l] 72 * 190.3 *
fT3 [3.2-6.0 pmol/l] 7.8 * 6.5 *
TSH receptor antibodies [< 1.8 IU/l] 3.313 * 9.7 *
Thyroid Peroxidase Antibodies (TPOAb) [<60 U/ml] 570.9 * 4,944 *
Thyroglobulin Antibodies [<30 U/ml] 45.0 * 141.1 *
TSH: thyroid stimulating hormone, fT3: triiodothyronine, fT4: thyroxine. * = out of range.
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Figure 1 Timeline of TSH and fT4 for twin A.
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artery disease and chronic obstructive pulmonary disease
due to cigarette smoking with more than 50 pack years
have to be noticed.
Discussion and conclusions
Autoimmune thyroid diseases including Graves’ disease
and Hashimoto’s thyroiditis are caused by immune re-
sponse to self-thyroid antigens and affect approximately
2-5% of the general population [8,9]. Genetic susceptibil-
ity in combination with external factors such as smoking,
viral/bacterial infection, and chemicals is believed to ini-
tiate the autoimmune response against thyroid antigens
[3,8]. Graves’ disease is considered as a multifactorial dis-
order in which genetic susceptibility interacts with envir-
onmental and endogenous factors to cause disease [10].
Previous family and twin studies indicated that Graves’
disease has a heritable component [11-14]. Dittmar et al.
reported that the risk for developing autoimmune
thyroid diseases was 16-fold and 15-fold increased in
children and siblings, respectively, of patients with auto-
immune thyroid diseases [12]. The risk for developing
Graves’ disease was enhanced 7-fold in both children and
siblings. Family studies have also shown that some auto-
immune disease cluster in families and genetic studies
have been able to show shared susceptibility genes
[11,13]. The highest familial risk for offspring of affected
parents was noted for Graves’ disease with standardized
incidence ratio (SIR) 3.87, followed by toxic nodular
goitre (3.37) and nontoxic goitre (3.15). Familial risks
were higher for affected siblings: toxic nodular goitre
(11.66), Graves’ disease (5.51), and nontoxic goitre (5.40).
Villanueva et al. studied 155 patients (131 with Graves’
disease and 24 with Hashimoto’s thyroiditis) with reliable
information on the presence or absence of autoimmune
thyroid disease in siblings [14]. Nine subjects had siblings
with Graves’ disease and 13 subjects had siblings with
Hashimoto’s thyroiditis.
Biometric twin modelling showed that approximately
75% of the total phenotypic variance in autoimmune thy-
roid disease was due to genetic effects [9,15,16]. The risk
was higher for monozygotic than for dizygotic twins
[17,18]. The aggregation of thyroid autoantibodies seemed
to be genetically determined. Healthy first-degree relatives
to patients with autoimmune thyroid disease showed a
significant clustering of thyroid autoantibodies. Healthy
monozygotic and dizygotic twin siblings to twins with
autoimmune thyroid disease differed, however, in the
prevalence of thyroid autoantibodies [18].
Apart from the present case and the recent case reports
with Graves’ disease in twins [5-7], the combination of
Graves’ disease and primary hypothyroidism in female
twins has also been reported [19,20]. Aust et al. descri-
bed twins where simultaneously Graves’ disease and
Hashimoto’s thyroiditis occurred in monozygotic twins
[19]. We report here the rare situation that hyperthyroid-
ism was found in the mother of twins and both of her
twin children. O’Connor et al. described a situation where
premature twins of a mother with Graves’ disease devel-
oped concurrent hyperthyroidism and hypothyroidism
[21]. In addition to twins with Graves’ disease, cases
of subacute thyroiditis have been reported for siblings
[22,23] and twins [24].
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Figure 2 Timeline of TSH and fT4 for twin B.
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Both the twins and the mother were cigarette smoking.
The impact of environmental triggers such as cigarette
smoking, birth characteristics, infection with Yersinia
enterocolitica, microchimerism and degree of X chromo-
some inactivation (XCI) has been evaluated by investi-
gating autoimmune thyroid disease in twin pairs [16].
These studies indicate that smoking, Y. enterocolitica in-
fection and skewed XCI may be causally associated with
clinically overt autoimmune thyroid disease, but not
with the presence of thyroid autoantibodies in euthyroid
subjects [16].
A limitation of this case report is the fact that we do not
distinguish between somatic mutations in toxic adenoma
and germ cell mutations in autoimmune hyperthyroidism.
Practical applications
Our case report gives some additional hints to a possible
genetic susceptibility or at least genetic vulnerability for
Grave’s disease in combination with external factors, such
as smoking, viral/bacterial infection, and chemical agents.
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